KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EPS (Weighted Average and Diluted): 2010-2024

Historic EPS (Weighted Average and Diluted) for Arbutus Biopharma (ABUS) over the last 14 years, with Dec 2024 value amounting to -$0.38.

  • Arbutus Biopharma's EPS (Weighted Average and Diluted) rose 60.00% to -$0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.23, marking a year-over-year increase of 46.51%. This contributed to the annual value of -$0.38 for FY2024, which is 13.64% up from last year.
  • As of FY2024, Arbutus Biopharma's EPS (Weighted Average and Diluted) stood at -$0.38, which was up 13.64% from -$0.44 recorded in FY2023.
  • Over the past 5 years, Arbutus Biopharma's EPS (Weighted Average and Diluted) peaked at -$0.38 during FY2024, and registered a low of -$1 during FY2020.
  • In the last 3 years, Arbutus Biopharma's EPS (Weighted Average and Diluted) had a median value of -$0.44 in 2023 and averaged -$0.43.
  • Data for Arbutus Biopharma's EPS (Weighted Average and Diluted) shows a peak YoY soared of 44.58% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Arbutus Biopharma's EPS (Weighted Average and Diluted) stood at -$1 in 2020, then climbed by 17.00% to -$0.83 in 2021, then skyrocketed by 44.58% to -$0.46 in 2022, then grew by 4.35% to -$0.44 in 2023, then increased by 13.64% to -$0.38 in 2024.